Oncimmune Holdings PLC Notice of Full Year results (0268Q)
25 October 2021 - 05:00PM
UK Regulatory
TIDMONC
RNS Number : 0268Q
Oncimmune Holdings PLC
25 October 2021
25 October 2021
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Notice of full year results ended 31 May 2021 and investor
presentations
Oncimmune Holdings plc (AIM: ONC.L), the leading global
immunodiagnostics group , will be announcing its full year results
for the year ended 31 May 2021 on Tuesday, 2 November 2021.
Analyst and investor presentations
Dr Adam M Hill, Chief Executive Officer, together with Matthew
Hall, Chief Financial Officer, will host a virtual presentation and
conference call for analysts at 10:00 GMT on the day of the
results. For conference call details please contact Alex Davis of
FTI Consulting at Alexander.Davis@fticonsulting.com or 020 3727
1000.
The management team will also host on Investor Meet Company, a
live presentation of the results at 15:00 GMT.
-- The online presentation will be open to all existing
shareholders and potential new investors
-- Questions can be submitted pre-event via your Investor Meet
Company dashboard up until 09:00 GMT the day before the meeting or
at any time during the live presentation. Responses to the Q&A
will be published at the earliest opportunity on the Investor Meet
Company platform
-- Investor feedback can also be submitted directly to
management immediately following the event
Access to Investor Meet Company is free and interested parties
can register to attend the presentation via the following link:
https://www.investormeetcompany.com/oncimmune-holdings-plc/register-investor
Attendees who have already registered on the Investor Meet
Company platform to meet the Company will automatically receive an
invitation to the presentation.
For further information:
Oncimmune Holdings plc
Dr Adam M Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Daniel Harris, James Hornigold
+44 (0)20 3829 5000
Singer Capital Markets (Joint Broker)
Aubrey Powell, Harry Gooden, George Tzimas, James Fischer
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Nigel Barnes, Nigel Birks
+44 (0)20 3705 9321
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
Oncimmune@fticonsulting.com
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a leading immunodiagnostics developer, primarily
focused on the growing fields of immuno-oncology, autoimmune
disease and infectious diseases. Oncimmune has a diversified and
growing revenue both from its portfolio of diagnostic products to
detect early-stage cancer and its contract discovery and
development service business whose platform delivers actionable
insights into therapies to the Company's pharmaceutical and biotech
partners .
Our understanding of the immune system enables us to harness its
sophisticated response to disease to detect cancer earlier and to
support the development of better therapies. The key to improving
cancer survival is early detection and better selection for
therapy. As a company, we are driven by our passion to improve
cancer survival and to give people extra time.
Oncimmune's ImmunoINSIGHTS platform enables life science
organisations to optimise drug development and delivery, leading to
more effectively targeted and safer treatments for patients.
Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and
help identify cancer on average four years earlier than standard
clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung,
targets a vast market estimated to grow to GBP3.8bn by 2024. With
over 200,000 tests already performed for patients worldwide and its
use being supported by peer reviewed data in over 12,000 patients,
we are poised to become an integral component of future lung cancer
detection programmes, globally.
Oncimmune's diagnostic products business is located at its
laboratory facility in Nottingham, UK and its ImmunoINSIGHTS
service business at its discovery research centre in Dortmund,
Germany. The ImmunoINSIGHTS business development team are based in
the US and Oncimmune is seeking to replicate the Dortmund facility
in the US in the medium term.
For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORGZMZGGDFGMZZ
(END) Dow Jones Newswires
October 25, 2021 02:00 ET (06:00 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Feb 2024 to Mar 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From Mar 2023 to Mar 2024